Healthcare Stocks Retreated: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), Spark Therapeutics, Inc. (NASDAQ:ONCE), Regulus Therapeutics Inc. (NASDAQ:RGLS), Alphatec Holdings, Inc. (NASDAQ:ATEC), Ohr Pharmaceutical (NASDAQ:OHRP)

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) reported Net product sales for the second quarter of 2015 were $34.3 million, representing a 24% increase over the same quarter last year and a 22% increase over the first quarter of 2015. Operating income for second quarter 2015 was $3.1 million, compared to operating income of $3.8 million in the same quarter last year. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) belongs to Healthcare sector. Its net profit margin is 25.80% and weekly performance is -6.01%. On last trading day company shares ended up $19.22. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) distance from 50-day simple moving average (SMA50) is 9.79%.

Spark Therapeutics, Inc. (NASDAQ:ONCE) reported net loss applicable to common stockholders for the three months ended June 30, 2015 was $14.3 million, or ($0.60) basic and diluted net loss per common share, as compared with a net loss applicable to common stockholders of $4.2 million, or ($0.79) basic and diluted net loss per common share for the three months ended June 30, 2014. Spark Therapeutics, Inc. (NASDAQ:ONCE) shares moved down -10.84% in last trading session and ended the day at $57.50. ONCE return on assets is -28.30%. Spark Therapeutics, Inc. (NASDAQ:ONCE) quarterly performance is -3.13%.

Regulus Therapeutics Inc. (NASDAQ:RGLS) on Tuesday reported a loss of $21 million in its second quarter. The San Diego-based company said it had a loss of 41 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 31 cents per share. ON 05 August, Regulus Therapeutics Inc. (NASDAQ:RGLS) shares moved down -6.69% and was closed at $7.25. Regulus Therapeutics Inc. (NASDAQ:RGLS) year to date (YTD) performance is -54.80%.

Alphatec Holdings, Inc. (NASDAQ:ATEC) reported Consolidated net revenues for the second quarter of 2015 were $46.6 million as reported, down 12.3% compared to $53.2 million reported for the second quarter of 2014, or down 5.6% on a constant currency basis. Consolidated revenues were impacted by $3.6 million in the second quarter due to declines in the valuation of the Japanese Yen and Euro against the U.S. Dollar. Alphatec Holdings, Inc. (NASDAQ:ATEC) ended the last trading day at $0.78. Company weekly volatility is calculated as 18.06% and price to cash ratio as 6.83. Alphatec Holdings, Inc. (NASDAQ:ATEC) showed a weekly performance of -42.65%.

Ohr Pharmaceutical (NASDAQ: OHRP) announced that Jason S. Slakter, MD, has been appointed Chief Executive Officer, effective August 7, 2015. He succeeds CEO and founder Dr. Irach Taraporewala, who will become Chief Technology Officer and be responsible for the leadership and execution of the Company’s sustained release drug development programs, among other responsibilities. Dr. Taraporewala will continue to serve on the Company’s board of directors.Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) shares moved down -7.84% in last trading session and ended the day at $2.82. OHRP return on assets is -35.60%. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) quarterly performance is 2.17%.

Leave a Reply

Your email address will not be published. Required fields are marked *